The Efficacy of Natalizumab versus Fingolimod for Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review, Indirect Evidence from Randomized Placebo-Controlled Trials and Meta-Analysis of Observational Head-to-Head Trials

BACKGROUND: Although Fingolimod (FGD) and Natalizumab (NTZ) appear to be effective in relapsing-remitting multiple sclerosis (RRMS), they have never been directly compared in a randomized clinical trial (RCT). METHODS AND FINDINGS: We evaluated the comparative efficacy of FGD vs. NTZ using a meta-an...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsivgoulis, Georgios, Katsanos, Aristeidis H., Mavridis, Dimitris, Grigoriadis, Nikolaos, Dardiotis, Efthymios, Heliopoulos, Ioannis, Papathanasopoulos, Panagiotis, Karapanayiotides, Theodoros, Kilidireas, Constantinos, Hadjigeorgiou, Georgios M., Voumvourakis, Konstantinos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042498/
https://www.ncbi.nlm.nih.gov/pubmed/27684943
http://dx.doi.org/10.1371/journal.pone.0163296

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042498/
https://www.ncbi.nlm.nih.gov/pubmed/27684943
http://dx.doi.org/10.1371/journal.pone.0163296

Ejemplares similares